Table 1.
Healthy controls | RRMS | p | |
---|---|---|---|
n | 20 | 29 | |
Age | 35.1±1.9 | 37.5±1.6 | .33 |
Male/Female | 2 / 18 | 4 / 25 | .69 |
Brain atrophy (BPF) | 0.84±0.004 | 0.82±0.005 | .006 |
Lesion volume [cm3] | N/A | 7.1±2.0 | |
EDSS | N/A | 2.5±0.2 | |
Disease duration | N/A | 6.7±1.0 | |
DMT (None, IFNβ, GA, Nat) | N/A | 7 / 13 / 8 / 1 | |
BDI-II | 1.6±0.5 | 9.5±1.6 | <.001 |
BAI | 2.1±0.6 | 8.3±1.4 | .001 |
SSRI treatment | 0 | 6 |
BPF=Brain Parenchymal Fraction; EDSS=Expanded Disability Status Scale, DMT=disease-modifying therapy; IFNβ=Interferon-β GA=Glatiramer Acetate; Nat=Natalizumab; BDI=Beck Depression Inventory, BAI=Beck Anxiety Inventory; SSRI=Selective serotonin reuptake inhibitor